THE INTERNATIONAL NORMALIZED RATIO - A GUIDE TO UNDERSTANDING AND CORRECTING ITS PROBLEMS

被引:161
作者
HIRSH, J
POLLER, L
机构
[1] MCMASTER UNIV,DEPT MED,HAMILTON,ON,CANADA
[2] UNIV MANCHESTER,SCH MED,DEPT PATHOL SCI,MANCHESTER,LANCS,ENGLAND
关键词
D O I
10.1001/archinte.154.3.282
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
With the increasing use of the international normalized ratio (INR) to monitor warfarin therapy, a number of problems with prothrombin time (PT) testing have been identified that have led some laboratory physicians to question the reliability of the INR.(1) This is ironic, because it was the introduction of the INR system that brought to light some of the long-standing problems with the technique of PT monitoring. However, these problems are not insurmountable if a compromise can be reached between the expectations of laboratory physicians and of clinicians. Thus, the laboratory physician seeks a perfect assay system, which in the case of the INR is unattainable at present, because of differences in PT reagents and methods. In contrast, the clinician is satisfied with a system of monitoring that provides safe and effective warfarin dosing. This goal can be achieved provided that certain details of PT testing are observed. In this communication, which is directed to practicing clinicians, the potential problems with the INR system are discussed, their clinical relevance is critically reviewed, and solutions are offered.
引用
收藏
页码:282 / 288
页数:7
相关论文
共 29 条
[1]   IMPRECISION OF PROTHROMBIN TIME MONITORING OF ORAL ANTICOAGULATION - A SURVEY OF HOSPITAL LABORATORIES [J].
ANSELL, JE .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1992, 98 (02) :237-239
[2]  
BUSSEY HI, 1992, ARCH INTERN MED, V152, P278
[3]   COMPARISON OF 2 AUTOMATED COAGULOMETERS AND THE MANUAL TILT-TUBE METHOD FOR THE DETERMINATION OF PROTHROMBIN TIME [J].
DANGELO, A ;
SEVESO, MP ;
DANGELO, SV ;
GILARDONI, F ;
MACAGNI, A ;
MANOTTI, C ;
BONINI, P .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1989, 92 (03) :321-328
[4]  
FURIE B, 1990, BLOOD, V75, P344
[6]  
HIRSH J, 1991, NEW ENGL J MED, V324, P1865
[7]   ORAL ANTICOAGULANTS - MECHANISM OF ACTION, CLINICAL EFFECTIVENESS, AND OPTIMAL THERAPEUTIC RANGE [J].
HIRSH, J ;
DALEN, JE ;
DEYKIN, D ;
POLLER, L .
CHEST, 1992, 102 (04) :S312-S326
[8]   DIFFERENT INTENSITIES OF ORAL ANTICOAGULANT-THERAPY IN THE TREATMENT OF PROXIMAL-VEIN THROMBOSIS [J].
HULL, R ;
HIRSH, J ;
JAY, R ;
CARTER, C ;
ENGLAND, C ;
GENT, M ;
TURPIE, AGG ;
MCLOUGHLIN, D ;
DODD, P ;
THOMAS, M ;
RASKOB, G ;
OCKELFORD, P .
NEW ENGLAND JOURNAL OF MEDICINE, 1982, 307 (27) :1676-1681
[9]  
KAZAMA M, 1990, THROMB HAEMOSTASIS, V64, P535
[10]   COMPARISON OF NATIVE PROTHROMBIN ANTIGEN WITH THE PROTHROMBIN TIME FOR MONITORING ORAL ANTICOAGULANT PROPHYLAXIS [J].
KORNBERG, A ;
FRANCIS, CW ;
PELLEGRINI, VD ;
GABRIEL, KR ;
MARDER, VJ .
CIRCULATION, 1993, 88 (02) :454-460